EndoTool is a highly sophisticated glucose management system designed to improve the safety and quality of care, as related to the treatment of hyperglycemia (high blood glucose). It calculates the dose of intravenous (I.V.) insulin needed to effectively control blood glucose levels. EndoTool is a 510(k) approved system. It is a dynamic and adaptive software, which identifies individual patient responses to I.V. insulin to help manage current and predict future dosage levels. Replacing the traditional paper-based system used to manage insulin treatment, EndoTool helps clinicians maintain the appropriate precision to manage blood glucose levels in a variety of hospital settings. Overly aggressive insulin therapy can increase the risk of hypoglycemia (low blood glucose), an independent risk factor for mortality (2)(3). EndoTool software can operate on a hospital's existing computer system, and is currently available for use on stand-alone personal computers or in bedside terminal environments.
Hospira is targeting a 510(k) submission to the U.S. Food and Drug Administration (FDA) for the integrated Symbiq/EndoTool system by the end of the year.
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of gener
|SOURCE Hospira, Inc.|
Copyright©2009 PR Newswire.
All rights reserved